Public hearing to evaluate achondroplasia treatment plan - EMA
The Paediatric Committee (PDCO) at the European Medicines Agency (EMA), is currently evaluating the development plans for a proposed treatment for achondroplasia.
The PDCO would like to reach out to patients or carers living in EUROPE to gather their experiences of living with achondroplasia, as well as their expectations in terms of benefits and risk-acceptance for potential new treatment. This will help PDCO to better understand, and take into consideration, patients' views and needs.
The PDCO would like to reach out to patients or carers living in EUROPE to gather their experiences of living with achondroplasia, as well as their expectations in terms of benefits and risk-acceptance for potential new treatment. This will help PDCO to better understand, and take into consideration, patients' views and needs.
If you live in Europe and have achondroplasia or are a caregiver of a child with achondroplasia, answer and share this questionnaire (only available in English)
https://ec.europa.eu/eusurvey/runner/AchondroplasiaSurvey
The deadline for responses is 22 January 2020.
Thank you!
https://ec.europa.eu/eusurvey/runner/AchondroplasiaSurvey
The deadline for responses is 22 January 2020.
Thank you!